Frazer Hall News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Progress in the LIBERATE trial was presented at the American Transplant

Expansion of existing partnership will utilize novel insights into causal biology within auto-immune disorders to identify novel targets for drug ...

Japan, South Korea, and the African subcontinent are now covered by the Alliance. With the addition of two new WODA members – Nxera Pharma (formerly Sosei Heptares) and Veld Pharmaceuticals – WODA now provides access to over 200 million rare disease patients. TOKYO and ZUG, Switzerland, April 08, 2024 (GLOBE NEWSWIRE) -- The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in comp

Tokyo, Japan and Cambridge, UK, 3 April 2024 - Nxera Pharma (“Nxera” or “the Company”; TSE: 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Japan pharmaceutical sector expert, Mr. Patrick Branch, as Head of Business Development for Japan and the APAC region. Mr. Branch will join Nxera’s global Business Development team that is led by Dr. Marcus Messenger. He will be based in Nxera’s Tokyo office and will oversee Japan and regional disease area strateg

Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,